ALGS · Aligos Therapeutics, Inc.
$6.93
-0.14 (-1.98%)
At close · Aug 28
Going-concern doubt
— cleared Aug 6, 2026
The latest filing no longer states the doubt (first flagged May 7, 2026).
View the 10-Q filed Aug 6, 2026Market Cap
$26.95M
Shares
3.59M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$2.19M
-39.5%
FY2025
Net Income
-$24.19M
+81.6%
FY2025
Operating Margin
-4024.93%
-1556pp
FY2025
Diluted EPS
-$2.45
+88.3%
FY2025
Operating Cash Flow
-$82.5M
-2.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $3.74M | $2.19M | $3.61M | $6.19M | $0 | $0 | $0 | — | |
| $1.3M | $2.2M | $1.7M | $4.3M | $1.5M | — | — | — | |
| $88.38M | $69.45M | $70.27M | $73.04M | $85.08M | $104.15M | $79.89M | $44.04M | |
| $22.14M | $20.72M | $22.83M | $30.62M | $26.41M | $28.53M | $17.94M | $10.01M | |
| $110.51M | $90.17M | $93.1M | $103.66M | $111.49M | $132.68M | $97.83M | $54.04M | |
| -$78.99M | -$87.99M | -$89.15M | -$88.13M | -$97.58M | -$128.32M | -$97.83M | -$54.04M | |
| — | -4024.93% | -2468.96% | -1423.47% | — | — | — | — | |
| -$72.75M | -$23.88M | -$130.88M | -$86.88M | -$95.94M | -$128.19M | -$108.38M | -$52.18M | |
| $3.21M | $314K | $331K | $795K | $106K | $143K | $161K | $85K | |
| -$75.96M | -$24.19M | -$131.21M | -$87.68M | -$96.05M | -$128.33M | -$108.54M | -$52.26M | |
| — | -1106.72% | -3633.65% | -1416.23% | — | — | — | — | |
| -$75.95M | -$24.18M | -$131.31M | -$87.54M | -$96.1M | -$127.69M | -$108.62M | -$52.38M | |
| USD/shares | -$8.39 | -$2.45 | -$20.94 | -$34.20 | -$56.25 | — | — | — |
| USD/shares | -$1.16 | -$2.45 | -$20.94 | -$34.20 | -$56.25 | — | — | — |
| shares | — | 9.88M | 6.26M | 2.56M | 1.71M | 1.59M | 399.53K | 80.29K |
| shares | — | 9.88M | 6.26M | 2.56M | 1.71M | 1.59M | 399.53K | 80.29K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.48×
EV/EBIT
—
P/E (TTM)
—
Peer median 5.70×
Peer medians compare against the 244 similar-size Biotechnology companies (of 517 listed).
Key facts
CIK
1799448
CUSIP
01626L204
13F (30d)
28 filings
28 filers
Visit website
Investor relations